2018 American Transplant Congress
Biomaterial-Based Localized and Controlled Delivery of Tofacitinib to Actuate Enhanced Costimulation Blockade and Promote Long-Term Transplant Survival
Complications from long-term use of calcineurin inhibitors remain a major issue for transplant patients and alternative therapies are highly needed. We investigated two innovative drug…2018 American Transplant Congress
Optimal Anti-Thymocyte Globulin Dose for Induction Immunosuppression in Kidney Transplantation
Organ Transplant Program, Swedish Medical Center, Seattle, WA.
Anti-thymocyte globulin (ATG) is used as induction immunosuppression in kidney transplantation to prevent allograft rejection. ATG causes dose-dependent lymphocyte depletion, yet optimal dose is unknown.…2018 American Transplant Congress
Decreased Expression of Pro-Carcinogenic Genes Following Tacrolimus to Sirolimus Conversion in Liver Transplant Recipients
Long-term survival post-transplant is significantly impacted by malignancy. mTOR-inhibitors (mTORis) have anti-neoplastic properties and are associated with a decreased incidence of certain malignancies compared to…2018 American Transplant Congress
Assessment of Peak Levels and Metabolism Rates in African American (AA) and Non-AA Kidney Transplant Recipients (KTR) on Immediate-Release Tacrolimus (IR-tac)
Trough-to-daily dose (C/D) ratio has been used as a simple method for evaluation of IR-tac metabolism rate. Recent studies have shown that fast metabolizers defined…2018 American Transplant Congress
Can We Optimise Immunosuppression Strategies in Our Older Renal Transplant Recipients?
Renal transplantation provides a survival advantage for patients including those with multiple co-morbidities and older age compared to remaining on dialysis. The optimal immunosuppressive regime…2018 American Transplant Congress
De Novo Use of Extended Released Tacrolimus (Meltdose, EnvasusR)) after OLT – Does the Colonic Resorption Influences the Outcome?
Department of Transplantation, Medical University of Vienna, Vienna, Austria.
Introduction: Immunosuppression after OLT has reached a quite high standard with an excellent evidence base. However, there is still a lack of data for the…2018 American Transplant Congress
The Clinical Efficacy of Seasonal Influenza Vaccination – Characteristics of Two Outbreaks of Influenza A(H1N1) in Immunocompromised Patients
A. Background. Influenza A(H1N1) causes serious complications in immunocompromised patients. The efficacy of seasonal influenza vaccination in transplant recipients and patients receiving chemotherapy has been…2018 American Transplant Congress
Outcomes in Liver Transplant Patients on Renal Sparing Protocol
As liver transplant outcomes have improved, long term native kidney function has taken a critical role in patient survival. Calcineurin inhibitors (CNIs), such as Tacrolimus…2018 American Transplant Congress
Belatacept in Kidney Transplant Recipients with Preformed Donor Specific Anti-HLA Antibodies: Results of the BELACOR Trial
IntroductionAntibody-mediated rejection (ABMR) is currently a critical question in kidney transplant recipient with immunological risk factors such as pre transplant donor-specific anti HLA antibodies (DSA).…2018 American Transplant Congress
Identification of Anti-Inflammatory and Pro-Inflammatory Gut Microbiota That Determine Graft Survival
Introduction: The gut microbiota induce and train the host immune system. Whether microbiota from contrasting environments of colitic or pregnant mice are pro- or anti-inflammatory…
- « Previous Page
- 1
- …
- 68
- 69
- 70
- 71
- 72
- …
- 138
- Next Page »